Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has resolved to hold its 13th Annual General Meeting of Shareholders on March 15, 2024, to submit agenda items including the approval of FY2023 financial statements and the approval of the limit on director remuneration.
📊 [Key Disclosure Details & Financial Figures]
- Meeting Type: 13th Annual General Meeting of Shareholders
- Date & Time: March 15, 2024, at 09:00 KST
- Location: Room 113, 1st Floor, Songdo Convensia (123 Central-ro, Yeonsu-gu, Incheon)
- Meeting Purpose & Agenda Items:
- Report Items: Report on Transactions with Related Parties, Audit Report, Business Report, Report on the Operational Status of Internal Accounting Control System
- Voting Items:
- Item 1: Approval of Financial Statements for the 13th Fiscal Year (2023.01.01 ~ 12.31)
- Item 2: Approval of Limit on Remuneration for Directors
- Board Resolution Date: February 14, 2024
- Board Attendance: 4 Outside Directors attended (0 absent)
- Other Remarks: Details are subject to change based on corporate circumstances
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Shareholder Approval of Agenda Items and Finalized Financial Figures
This disclosure provides advance notice of the upcoming 13th Annual General Meeting of Shareholders along with its proposed agenda items. Tracking whether the submitted proposals gain shareholder approval is essential to verify the final confirmation of the fiscal year’s financial statements and the operational limits for the board. Investors can confirm the voting results and finalized figures through subsequent disclosures such as the ‘Results of General Meeting of Shareholders’ and the Annual Report.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
